Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775435 | 1.00 | KMT2A (0.56) | KMT2AMAPK1HCAR2DAOTBXAS1 | |
| SCHEMBL8920408 | 0.85 | MAPK1 (0.66) | KMT2AMAPK1HCAR2TBXAS1MAPT | |
| SCHEMBL8920416 | 0.85 | MAPK1 (0.66) | KMT2AMAPK1HCAR2TBXAS1MAPT | |
| SCHEMBL17157651 | 0.85 | DAO (0.42) | KMT2AMAPK1DAORAB9AMAPT | |
| SCHEMBL17157652 | 0.85 | DAO (0.42) | KMT2AMAPK1DAORAB9AMAPT | |
| SCHEMBL4486603 | 0.84 | GLA (0.44) | KMT2AMAPK1DAORAB9AMAPT | |
| SCHEMBL4486601 | 0.84 | GLA (0.44) | KMT2AMAPK1DAORAB9AMAPT | |
| SCHEMBL28774607 | 0.82 | CES2 (0.41) | KMT2AMAPK1DAORAB9AMAPT | |
| SCHEMBL68058 | 0.78 | CA12 (0.46) | KMT2AMAPK1HCAR2RAB9AMAPT | |
| SCHEMBL3475868 | 0.78 | ALDH1A1 (0.45) | KMT2AMAPK1DAORAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-18 | — | — | US | disclosed |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNITED STATES GOVERNMENT | 2021-12-23 | — | — | US | disclosed |
| EP-3880684-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3880200-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | University of Virginia Patent Foundation (US) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102243-A2 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102245-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-05-22 | — | — | WO | disclosed |
| US-8304438-B2 | Heteroarylacrylamides and their use as pharmaceuticals | SANOFI (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8188291-B2 | Heteroaryl-substituted carboxamides and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-6268354-B1 | Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
| US-6172061-B1 | AIDS THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-6166006-A | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1039899-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| EP-1040103-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999032100-A2 | PHARMACEUTICAL COMPOSITION FOR ANTAGONIZING CCR5 COMPRISING ANILIDE DERIVATIVE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999032468-A1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-07-01 | — | — | WO | disclosed |
| US-5039684-A | Absorption when administered orally | VALEAS S. P. A. (IT) | 1991-08-13 | — | — | US | disclosed |
| EP-0384450-A1 | Tetrazole amide derivatives of heterocyclic alkenyl acids and their use as antiallergic substances | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1990-08-29 | — | — | EP | disclosed |
| US-4093622-A | Pyridine esters of cyclopropane-carboxylic acid | ZOECON CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017534-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | PTP4A3, PTPRC, PTPRF | KMT2A 1186/4885MAPK1 2760/4885HCAR2 2701/4885 |
| US-12202839-B2 | In-flow photooxygenation of aminothienopyridinones generates PTP4A3 phosphatase inhibitors | PTP4A3, PTPRO, PTPRC | KMT2A 1072/4885MAPK1 2829/4885HCAR2 3208/4885 |
| US-20210395266-A1 | IN-FLOW PHOTOOXYGENATION OF AMINOTHIENOPYRIDINONES GENERATES NOVEL PTP4A3 PHOSPHATASE INHIBITORS | PTP4A3, PTPRO, PTPRC | KMT2A 1128/4885MAPK1 2551/4885HCAR2 2993/4885 |
| US-12227515-B2 | In-flow photooxygenation of aminothienopyridinones generates novel PTP4A3 phosphatase inhibitors | PTP4A3, PTPRC, PTPRF | KMT2A 1186/4885MAPK1 2760/4885HCAR2 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.